Key result
High-dose vigabatrin achieved significantly higher rates of spasm cessation compared to low-dose vigabatrin (15.9% vs 7.0%; P=0.0375) in patients with newly diagnosed infantile spasms.
Why the study?
Does high-dose vigabatrin improve spasm cessation compared to low-dose vigabatrin in infants with newly diagnosed infantile spasms?
RCT (n=221)
Single-blind
Does high-dose vigabatrin improve spasm cessation compared to low-dose vigabatrin in infants with newly diagnosed infantile spasms?
Absolute Event Rate: 15.9% vs 7%
p-value: p=0.0375
High-dose vigabatrin is more effective than low-dose vigabatrin for achieving rapid spasm cessation in infants with newly diagnosed infantile spasms.
Authors
No takes yet. Share an insight, caveat, or question.
May favor high-dose vigabatrin for infantile spasms; leaves open confirmation of optimal dosing and outcomes in larger trials.
Elterman et al. (2010) conducted an RCT in Infantile spasms (n=221). Vigabatrin vs. Low dose vigabatrin (18-36 mg/kg/d) was evaluated on Spasm cessation (7 consecutive days of spasm freedom beginning within the first 14 days, confirmed by video-electroencephalogram) (p=0.0375). High-dose vigabatrin achieved significantly higher rates of spasm cessation compared to low-dose vigabatrin (15.9% vs 7.0%; P=0.0375) in patients with newly diagnosed infantile spasms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: